"Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@nl . . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@sq . "10.1007/BF00686549" . "art\u00EDculu cient\u00EDficu espubliz\u00E1u en xineru de 1995"@ast . "A Rogatko" . . . . . . . . . "artikull shkencor i botuar m\u00EB 01 janar 1995"@sq . "R F Ozols" . . . . . . . . . "scientific article published on 01 January 1995"@en . . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@nl . . "F P LaCreta" . . . . "1995-01-01T00:00:00Z"^^ . . . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@en . . . . . . . . . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@sq . . . . . . . . . "wetenschappelijk artikel"@nl . . . . . . . . . . . . . "C McAleer" . . . . "205-212" . . . . . "G R Hudes" . . . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@sq . . . . "im Januar 1995 ver\u00F6ffentlichter wissenschaftlicher Artikel"@de . "E M Newman" . . "35" . . . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@nl . . "A Hageboutros" . . . "\u043D\u0430\u0443\u043A\u043E\u0432\u0430 \u0441\u0442\u0430\u0442\u0442\u044F, \u043E\u043F\u0443\u0431\u043B\u0456\u043A\u043E\u0432\u0430\u043D\u0430 \u0432 \u0441\u0456\u0447\u043D\u0456 1995"@uk . "J Brennan" . "P J O'Dwyer" . . . . . . "7805178" . . . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@en . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@en . . . . . . . . . . "Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer"@en . . . . . . . . . . "3" .